{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:54:50Z","timestamp":1794272090605,"version":"4.9.0"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008440","name":"International Parkinson and Movement Disorder Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013301","name":"Parkinson's Foundation","doi-asserted-by":"publisher","award":["875333"],"award-info":[{"award-number":["875333"]}],"id":[{"id":"10.13039\/100013301","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Pathogenic variants in the <jats:italic>LRRK2<\/jats:italic> gene are one of the most commonly identifiable monogenic causes of Parkinson\u00b4s disease (PD, PARK-LRRK2). This systematic MDSGene literature review comprehensively summarizes published demographic, clinical, and genetic findings related to <jats:italic>LRRK2<\/jats:italic> variants (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/www.mdsgene.org\/\" ext-link-type=\"uri\">https:\/\/www.mdsgene.org\/<\/jats:ext-link>). Data on 4660 individuals with 283 different variants were curated. The median age at onset in the PD patients with available information was 56 years, notably, with approximately one-third having PD onset &lt;50 years. Tremor was the most frequently reported initial symptom and more common than reported in other dominantly inherited forms of PD. Of the 211 potentially PD-causing variants, 25 were classified as pathogenic or likely pathogenic, and the remaining 186 (88.2%) were variants of uncertain significance. p.G2019S was the most frequently reported pathogenic variant, followed by p.R1441G and p.R1441C. This systematic review represents the most extensive database on PARK-LRRK2 to date and provides a vital resource to improve precision medicine.<\/jats:p>","DOI":"10.1038\/s41531-025-00881-9","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T20:48:47Z","timestamp":1739825327000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Updated MDSGene review on the clinical and genetic spectrum of LRRK2 variants in Parkinson\u00b4s disease"],"prefix":"10.1038","volume":"11","author":[{"given":"Clara","family":"Kr\u00fcger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen-Yang","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alissa","family":"Buhrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenja L.","family":"Fahrig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Gabbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natascha","family":"Bahr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harutyun","family":"Madoev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie","family":"Marras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5121-1460","authenticated-orcid":false,"given":"Katja","family":"Lohmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,17]]},"reference":[{"key":"881_CR1","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/j.parkreldis.2020.09.024","volume":"80","author":"PA LeWitt","year":"2020","unstructured":"LeWitt, P. A. & Chaudhuri, K. R. Unmet needs in Parkinson disease: motor and non-motor. Parkinsonism Relat. Disord. 80, S7\u2013S12 (2020).","journal-title":"Parkinsonism Relat. Disord."},{"key":"881_CR2","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","volume":"397","author":"BR Bloem","year":"2021","unstructured":"Bloem, B. R., Okun, M. S. & Klein, C. Parkinson\u2019s disease. Lancet 397, 2284\u20132303 (2021).","journal-title":"Lancet"},{"key":"881_CR3","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/mds.27352","volume":"33","author":"M Kasten","year":"2018","unstructured":"Kasten, M. et al. Genotype-Phenotype relations for the Parkinson\u2019s Disease Genes Parkin, PINK1, DJ1: MDSGene systematic review. Mov. Disord. 33, 730\u2013741 (2018).","journal-title":"Mov. Disord."},{"key":"881_CR4","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1002\/mds.27527","volume":"33","author":"J Trinh","year":"2018","unstructured":"Trinh, J. et al. Genotype-phenotype relations for the Parkinson\u2019s disease genes SNCA, LRRK2, VPS35: MDSGene systematic review. Mov. Disord. 33, 1857\u20131870 (2018).","journal-title":"Mov. Disord."},{"key":"881_CR5","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s00702-022-02511-7","volume":"129","author":"G Hoglinger","year":"2022","unstructured":"Hoglinger, G. et al. GBA-associated PD: chances and obstacles for targeted treatment strategies. J. Neural. Transm. 129, 1219\u20131233 (2022).","journal-title":"J. Neural. Transm."},{"key":"881_CR6","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S1474-4422(24)00378-8","volume":"23","author":"SY Lim","year":"2024","unstructured":"Lim, S. Y. et al. Uncovering the genetic basis of Parkinson\u2019s disease globally: from discoveries to the clinic. Lancet Neurol. 23, 1267\u20131280 (2024).","journal-title":"Lancet Neurol."},{"key":"881_CR7","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1093\/brain\/awae142","volume":"147","author":"L Cook","year":"2024","unstructured":"Cook, L. et al. Parkinson\u2019s disease variant detection and disclosure: PD GENEration, a North American study. Brain 147, 2668\u20132679 (2024).","journal-title":"Brain"},{"key":"881_CR8","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1093\/brain\/awae188","volume":"147","author":"A Westenberger","year":"2024","unstructured":"Westenberger, A. et al. Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson\u2019s disease study. Brain 147, 2652\u20132667 (2024).","journal-title":"Brain"},{"key":"881_CR9","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1002\/mds.28416","volume":"36","author":"V Skrahina","year":"2021","unstructured":"Skrahina, V. et al. The Rostock International Parkinson\u2019s Disease (ROPAD) Study: protocol and Initial Findings. Mov. Disord. 36, 1005\u20131010 (2021).","journal-title":"Mov. Disord."},{"key":"881_CR10","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/mds.29297","volume":"38","author":"D Jennings","year":"2023","unstructured":"Jennings, D. et al. LRRK2 inhibition by BIIB122 in healthy participants and patients with Parkinson\u2019s Disease. Mov. Disord. 38, 386\u2013398 (2023).","journal-title":"Mov. Disord."},{"key":"881_CR11","doi-asserted-by":"publisher","first-page":"4092","DOI":"10.1021\/acschemneuro.4c00657","volume":"15","author":"S Tan","year":"2024","unstructured":"Tan, S., Liu, H. & Yao, X. LRRK2 inhibitors as promising treatment for Parkinson\u2019s Disease. ACS Chem. Neurosci. 15, 4092\u20134094 (2024).","journal-title":"ACS Chem. Neurosci."},{"key":"881_CR12","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/B978-0-444-63233-3.00014-2","volume":"147","author":"A Domingo","year":"2018","unstructured":"Domingo, A. & Klein, C. Genetics of Parkinson disease. Handb. Clin. Neurol. 147, 211\u2013227 (2018).","journal-title":"Handb. Clin. Neurol."},{"key":"881_CR13","doi-asserted-by":"publisher","first-page":"16842","DOI":"10.1073\/pnas.0507360102","volume":"102","author":"AB West","year":"2005","unstructured":"West, A. B. et al. Parkinson\u2019s disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl Acad. Sci. USA 102, 16842\u201316847 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"881_CR14","doi-asserted-by":"publisher","first-page":"e12813","DOI":"10.7554\/eLife.12813","volume":"5","author":"M Steger","year":"2016","unstructured":"Steger, M. et al. Phosphoproteomics reveals that Parkinson\u2019s disease kinase LRRK2 regulates a subset of Rab GTPases. Elife 5, e12813 (2016).","journal-title":"Elife"},{"key":"881_CR15","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.3390\/cells9122565","volume":"9","author":"GR Jeong","year":"2020","unstructured":"Jeong, G. R. & Lee, B. D. Pathological functions of LRRK2 in Parkinson\u2019s Disease. Cells 9, 2565 (2020).","journal-title":"Cells"},{"key":"881_CR16","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1002\/mds.23265","volume":"25","author":"JO Aasly","year":"2010","unstructured":"Aasly, J. O. et al. Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson\u2019s disease. Mov. Disord. 25, 2156\u20132163 (2010).","journal-title":"Mov. Disord."},{"key":"881_CR17","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1152\/physrev.00022.2010","volume":"91","author":"O Corti","year":"2011","unstructured":"Corti, O., Lesage, S. & Brice, A. What genetics tells us about the causes and mechanisms of Parkinson\u2019s disease. Physiol. Rev. 91, 1161\u20131218 (2011).","journal-title":"Physiol. Rev."},{"key":"881_CR18","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1042\/BCJ20220161","volume":"479","author":"AF Kalogeropulou","year":"2022","unstructured":"Kalogeropulou, A. F. et al. Impact of 100 LRRK2 variants linked to Parkinson\u2019s disease on kinase activity and microtubule binding. Biochem J. 479, 1759\u20131783 (2022).","journal-title":"Biochem J."},{"key":"881_CR19","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1002\/mds.29385","volume":"38","author":"M Borsche","year":"2023","unstructured":"Borsche, M. et al. The new p.F1700L LRRK2 variant causes parkinson\u2019s disease by extensively increasing kinase activity. Mov. Disord. 38, 1105\u20131107 (2023).","journal-title":"Mov. Disord."},{"key":"881_CR20","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1126\/science.aar5683","volume":"360","author":"DR Alessi","year":"2018","unstructured":"Alessi, D. R. & Sammler, E. LRRK2 kinase in Parkinson\u2019s disease. Science 360, 36\u201337 (2018).","journal-title":"Science"},{"key":"881_CR21","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1002\/mds.28452","volume":"36","author":"C Beetz","year":"2021","unstructured":"Beetz, C. et al. LRRK2 loss-of-function variants in patients with rare diseases: no evidence for a phenotypic impact. Mov. Disord. 36, 1029\u20131031 (2021).","journal-title":"Mov. Disord."},{"key":"881_CR22","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1001\/jamaneurol.2018.1885","volume":"75","author":"C Blauwendraat","year":"2018","unstructured":"Blauwendraat, C. et al. Frequency of loss of function variants in LRRK2 in Parkinson Disease. JAMA Neurol. 75, 1416\u20131422 (2018).","journal-title":"JAMA Neurol."},{"key":"881_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2023.1282174","volume":"15","author":"Z Landoulsi","year":"2023","unstructured":"Landoulsi, Z. et al. Genetic landscape of Parkinson\u2019s disease and related diseases in Luxembourg. Front. Aging Neurosci. 15, 1282174 (2023).","journal-title":"Front. Aging Neurosci."},{"key":"881_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2950","volume":"13","author":"MD Do","year":"2023","unstructured":"Do, M. D. et al. Clinical and genetic analysis of Vietnamese patients diagnosed with early-onset Parkinson\u2019s disease. Brain Behav. 13, e2950 (2023).","journal-title":"Brain Behav."},{"key":"881_CR25","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/mds.26651","volume":"31","author":"CM Lill","year":"2016","unstructured":"Lill, C. M. et al. Launching the movement disorders society genetic mutation database (MDSGene). Mov. Disord. 31, 607\u2013609 (2016).","journal-title":"Mov. Disord."},{"key":"881_CR26","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 17, 405\u2013424 (2015).","journal-title":"Genet Med."},{"key":"881_CR27","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1002\/mds.27710","volume":"34","author":"GM Riboldi","year":"2019","unstructured":"Riboldi, G. M. et al. Early-onset pathologically proven multiple system atrophy with LRRK2 G2019S mutation. Mov. Disord. 34, 1080\u20131082 (2019).","journal-title":"Mov. Disord."},{"key":"881_CR28","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s10072-023-07056-5","volume":"45","author":"T Carrer","year":"2024","unstructured":"Carrer, T. et al. Rapidly progressive multiple system atrophy in a patient carrying LRRK2 G2019S mutation. Neurol. Sci. 45, 309\u2013313 (2024).","journal-title":"Neurol. Sci."},{"key":"881_CR29","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/mds.26815","volume":"32","author":"M Sanchez-Contreras","year":"2017","unstructured":"Sanchez-Contreras, M. et al. Study of LRRK2 variation in tauopathy: progressive supranuclear palsy and corticobasal degeneration. Mov. Disord. 32, 115\u2013123 (2017).","journal-title":"Mov. Disord."},{"key":"881_CR30","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/mds.27225","volume":"33","author":"D Vilas","year":"2018","unstructured":"Vilas, D. et al. Clinical and neuropathological features of progressive supranuclear palsy in Leucine rich repeat kinase (LRRK2) G2019S mutation carriers. Mov. Disord. 33, 335\u2013338 (2018).","journal-title":"Mov. Disord."},{"key":"881_CR31","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1212\/01.wnl.0000239829.33936.73","volume":"67","author":"C Spanaki","year":"2006","unstructured":"Spanaki, C., Latsoudis, H. & Plaitakis, A. LRRK2 mutations on Crete: R1441H associated with PD evolving to PSP. Neurology 67, 1518\u20131519 (2006).","journal-title":"Neurology"},{"key":"881_CR32","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1212\/01.WNL.0000280574.17166.26","volume":"70","author":"AS Chen-Plotkin","year":"2008","unstructured":"Chen-Plotkin, A. S. et al. Corticobasal syndrome and primary progressive aphasia as manifestations of LRRK2 gene mutations. Neurology 70, 521\u2013527 (2008).","journal-title":"Neurology"},{"key":"881_CR33","volume":"7","author":"L Diaz-Feliz","year":"2022","unstructured":"Diaz-Feliz, L. et al. Generalized dystonia without Parkinsonism in an LRRK2 carrier. Clin. Park Relat. Disord. 7, 100157 (2022).","journal-title":"Clin. Park Relat. Disord."},{"key":"881_CR34","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.neulet.2005.07.044","volume":"389","author":"D Hernandez","year":"2005","unstructured":"Hernandez, D. et al. The dardarin G 2019 S mutation is a common cause of Parkinson\u2019s disease but not other neurodegenerative diseases. Neurosci. Lett. 389, 137\u2013139 (2005).","journal-title":"Neurosci. Lett."},{"key":"881_CR35","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/ana.20731","volume":"59","author":"OA Ross","year":"2006","unstructured":"Ross, O. A. et al. Lrrk2 and Lewy body disease. Ann. Neurol. 59, 388\u2013393 (2006).","journal-title":"Ann. Neurol."},{"key":"881_CR36","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/21678421.2023.2270705","volume":"25","author":"CG Olsen","year":"2024","unstructured":"Olsen, C. G. et al. Genetic overlap between ALS and other neurodegenerative or neuromuscular disorders. Amyotroph. Lateral Scler. Frontotemporal Degener. 25, 177\u2013187 (2024).","journal-title":"Amyotroph. Lateral Scler. Frontotemporal Degener."},{"key":"881_CR37","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3109\/00207454.2012.756485","volume":"123","author":"A De Rosa","year":"2013","unstructured":"De Rosa, A. et al. A case of restless leg syndrome in a family with LRRK2 gene mutation. Int. J. Neurosci. 123, 283\u2013285 (2013).","journal-title":"Int. J. Neurosci."},{"key":"881_CR38","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s40478-018-0617-y","volume":"6","author":"M Takanashi","year":"2018","unstructured":"Takanashi, M. et al. Isolated nigral degeneration without pathological protein aggregation in autopsied brains with LRRK2 p.R1441H homozygous and heterozygous mutations. Acta Neuropathol. Commun. 6, 105 (2018).","journal-title":"Acta Neuropathol. Commun."},{"key":"881_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.634666","volume":"15","author":"JO Aasly","year":"2021","unstructured":"Aasly, J. O. Inflammatory diseases among Norwegian LRRK2 mutation carriers. A 15-Years Follow-Up of a Cohort. Front. Neurosci. 15, 634666 (2021).","journal-title":"Front. Neurosci."},{"key":"881_CR40","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1016\/j.ajpath.2020.08.010","volume":"190","author":"ER Parrilla Castellar","year":"2020","unstructured":"Parrilla Castellar, E. R., Plichta, J. K., Davis, R., Gonzalez-Hunt, C. & Sanders, L. H. Somatic mutations in LRRK2 identify a subset of invasive mammary carcinomas associated with high mutation burden. Am. J. Pathol. 190, 2478\u20132482 (2020).","journal-title":"Am. J. Pathol."},{"key":"881_CR41","first-page":"5483","volume":"25","author":"SJ Lubbe","year":"2016","unstructured":"Lubbe, S. J. et al. Additional rare variant analysis in Parkinson\u2019s disease cases with and without known pathogenic mutations: evidence for oligogenic inheritance. Hum. Mol. Genet. 25, 5483\u20135489 (2016).","journal-title":"Hum. Mol. Genet."},{"key":"881_CR42","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/mdc3.13523","volume":"9","author":"R Mehanna","year":"2022","unstructured":"Mehanna, R. et al. Age cutoff for early-onset parkinson\u2019s disease: recommendations from the international parkinson and movement disorder society task force on early onset Parkinson\u2019s Disease. Mov. Disord. Clin. Pract. 9, 869\u2013878 (2022).","journal-title":"Mov. Disord. Clin. Pract."},{"key":"881_CR43","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.3390\/biomedicines11123118","volume":"11","author":"M Salemi","year":"2023","unstructured":"Salemi, M. et al. A next-generation sequencing study in a Cohort of Sicilian Patients with Parkinson\u2019s Disease. Biomedicines 11, 3118 (2023).","journal-title":"Biomedicines"},{"key":"881_CR44","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00702-017-1686-y","volume":"124","author":"OB Tysnes","year":"2017","unstructured":"Tysnes, O. B. & Storstein, A. Epidemiology of Parkinson\u2019s disease. J. Neural Transm. 124, 901\u2013905 (2017).","journal-title":"J. Neural Transm."},{"key":"881_CR45","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3233\/JND-200598","volume":"8","author":"L Over","year":"2021","unstructured":"Over, L., Bruggemann, N. & Lohmann, K. Therapies for Genetic Forms of Parkinson\u2019s disease: systematic literature review. J. Neuromuscul. Dis. 8, 341\u2013356 (2021).","journal-title":"J. Neuromuscul. Dis."},{"key":"881_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2023.105282","volume":"107","author":"P Prendes Fernandez","year":"2023","unstructured":"Prendes Fernandez, P. et al. Analysis of deep brain stimulation of the subthalamic nucleus (STN-DBS) in patients with monogenic PRKN and LRRK2 forms of Parkinson\u2019s disease. Parkinsonism Relat. Disord. 107, 105282 (2023).","journal-title":"Parkinsonism Relat. Disord."},{"key":"881_CR47","doi-asserted-by":"crossref","unstructured":"Leaver, K. et al. Clinical profiles and outcomes of deep brain stimulation in G2019S LRRK2 Parkinson disease. J. Neurosurg. 137, 184\u2013191 (2021).","DOI":"10.3171\/2021.7.JNS21190"},{"key":"881_CR48","doi-asserted-by":"publisher","first-page":"e187800","DOI":"10.1001\/jamanetworkopen.2018.7800","volume":"2","author":"CA Artusi","year":"2019","unstructured":"Artusi, C. A. et al. Association of subthalamic deep brain stimulation with motor, functional, and pharmacologic outcomes in patients with monogenic Parkinson Disease: a systematic review and meta-analysis. JAMA Netw. Open 2, e187800 (2019).","journal-title":"JAMA Netw. Open"},{"key":"881_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.895430","volume":"14","author":"GH Chan","year":"2022","unstructured":"Chan, G. H. The role of genetic data in selecting device-aided therapies in patients with advanced Parkinson\u2019s Disease: a mini-review. Front. Aging Neurosci. 14, 895430 (2022).","journal-title":"Front. Aging Neurosci."},{"key":"881_CR50","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/mds.29288","volume":"38","author":"EJ Vollstedt","year":"2023","unstructured":"Vollstedt, E. J. et al. Embracing monogenic Parkinson\u2019s Disease: the MJFF Global Genetic PD Cohort. Mov. Disord. 38, 286\u2013303 (2023).","journal-title":"Mov. Disord."},{"key":"881_CR51","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1002\/acn3.51776","volume":"10","author":"YL Sosero","year":"2023","unstructured":"Sosero, Y. L. & Gan-Or, Z. LRRK2 and Parkinson\u2019s disease: from genetics to targeted therapy. Ann. Clin. Transl. Neurol. 10, 850\u2013864 (2023).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"881_CR52","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/B978-0-323-85555-6.00018-7","volume":"193","author":"I Mata","year":"2023","unstructured":"Mata, I. et al. LRRK2: genetic mechanisms vs genetic subtypes. Handb. Clin. Neurol. 193, 133\u2013154 (2023).","journal-title":"Handb. Clin. Neurol."},{"key":"881_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe, W. et al. Parkinson disease. Nat. Rev. Dis. Prim. 3, 17013 (2017).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"881_CR54","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1002\/mds.27216","volume":"33","author":"CW Olanow","year":"2018","unstructured":"Olanow, C. W. & Stocchi, F. Levodopa: a new look at an old friend. Mov. Disord. 33, 859\u2013866 (2018).","journal-title":"Mov. Disord."},{"key":"881_CR55","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/S1474-4422(19)30195-4","volume":"18","author":"SY Lim","year":"2019","unstructured":"Lim, S. Y. et al. Parkinson\u2019s disease in the Western Pacific Region. Lancet Neurol. 18, 865\u2013879 (2019).","journal-title":"Lancet Neurol."},{"key":"881_CR56","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41572-021-00280-3","volume":"7","author":"D Aarsland","year":"2021","unstructured":"Aarsland, D. et al. Parkinson disease-associated cognitive impairment. Nat. Rev. Dis. Prim. 7, 47 (2021).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"881_CR57","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.parkreldis.2014.09.033","volume":"21","author":"RN Alcalay","year":"2015","unstructured":"Alcalay, R. N. et al. Neuropsychological performance in LRRK2 G2019S carriers with Parkinson\u2019s disease. Parkinsonism Relat. Disord. 21, 106\u2013110 (2015).","journal-title":"Parkinsonism Relat. Disord."},{"key":"881_CR58","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1001\/jamaneurol.2017.4019","volume":"75","author":"R Saunders-Pullman","year":"2018","unstructured":"Saunders-Pullman, R. et al. Progression in the LRRK2-Asssociated Parkinson Disease population. JAMA Neurol. 75, 312\u2013319 (2018).","journal-title":"JAMA Neurol."},{"key":"881_CR59","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1002\/humu.23645","volume":"39","author":"EA Rivera-Munoz","year":"2018","unstructured":"Rivera-Munoz, E. A. et al. ClinGen variant curation expert panel experiences and standardized processes for disease and gene-level specification of the ACMG\/AMP guidelines for sequence variant interpretation. Hum. Mutat. 39, 1614\u20131622 (2018).","journal-title":"Hum. Mutat."},{"key":"881_CR60","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.ajhg.2016.03.024","volume":"98","author":"LM Amendola","year":"2016","unstructured":"Amendola, L. M. et al. Performance of ACMG-AMP variant-Interpretation Guidelines among Nine laboratories in the clinical sequencing exploratory research consortium. Am. J. Hum. Genet 98, 1067\u20131076 (2016).","journal-title":"Am. J. Hum. Genet"},{"key":"881_CR61","unstructured":"Pratuseviciute, N. et al. Identification of over 45 leucine-rich repeat kinase 2 (LRRK2) activating variants. Movement Disorder Congress. Copenhagen (2023). https:\/\/www.mdscongress.org\/IC23-Late-BreakingAbstractBooklet.pdf"},{"key":"881_CR62","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41582-019-0301-2","volume":"16","author":"E Tolosa","year":"2020","unstructured":"Tolosa, E., Vila, M., Klein, C. & Rascol, O. LRRK2 in Parkinson disease: challenges of clinical trials. Nat. Rev. Neurol. 16, 97\u2013107 (2020).","journal-title":"Nat. Rev. Neurol."},{"key":"881_CR63","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/s41582-022-00681-2","volume":"18","author":"AH Tan","year":"2022","unstructured":"Tan, A. H., Lim, S. Y. & Lang, A. E. The microbiome-gut-brain axis in Parkinson disease - from basic research to the clinic. Nat. Rev. Neurol. 18, 476\u2013495 (2022).","journal-title":"Nat. Rev. Neurol."},{"key":"881_CR64","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.parkreldis.2015.07.011","volume":"21","author":"J Trinh","year":"2015","unstructured":"Trinh, J. et al. Novel LRRK2 mutations in Parkinsonism. Parkinsonism Relat. Disord. 21, 1119\u20131121 (2015).","journal-title":"Parkinsonism Relat. Disord."},{"key":"881_CR65","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.parkreldis.2008.03.004","volume":"14","author":"CS Lu","year":"2008","unstructured":"Lu, C. S. et al. Analysis of the LRRK2 Gly2385Arg variant in primary dystonia and multiple system atrophy in Taiwan. Parkinsonism Relat. Disord. 14, 393\u2013396 (2008).","journal-title":"Parkinsonism Relat. Disord."},{"key":"881_CR66","doi-asserted-by":"publisher","first-page":"e12313","DOI":"10.1097\/MD.0000000000012313","volume":"97","author":"T Bartonikova","year":"2018","unstructured":"Bartonikova, T. et al. New endemic familial parkinsonism in south Moravia, Czech Republic and its genetical background. Medicine 97, e12313 (2018).","journal-title":"Medicine"},{"key":"881_CR67","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1212\/01.wnl.0000240220.33950.0c","volume":"67","author":"A Rajput","year":"2006","unstructured":"Rajput, A. et al. Parkinsonism, Lrrk2 G2019S, and tau neuropathology. Neurology 67, 1506\u20131508 (2006).","journal-title":"Neurology"},{"key":"881_CR68","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.neuron.2004.11.005","volume":"44","author":"A Zimprich","year":"2004","unstructured":"Zimprich, A. et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601\u2013607 (2004).","journal-title":"Neuron"},{"key":"881_CR69","doi-asserted-by":"publisher","first-page":"214 e211","DOI":"10.1016\/j.neurobiolaging.2018.11.007","volume":"76","author":"C Blauwendraat","year":"2019","unstructured":"Blauwendraat, C. et al. Genetic analysis of neurodegenerative diseases in a pathology cohort. Neurobiol. Aging 76, 214 e211\u2013214.e219 (2019).","journal-title":"Neurobiol. Aging"},{"key":"881_CR70","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/ana.20484","volume":"57","author":"M Funayama","year":"2005","unstructured":"Funayama, M. et al. An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann. Neurol. 57, 918\u2013921 (2005).","journal-title":"Ann. Neurol."},{"key":"881_CR71","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.parkreldis.2008.07.010","volume":"15","author":"K Hasegawa","year":"2009","unstructured":"Hasegawa, K. et al. Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes. Parkinsonism Relat. Disord. 15, 300\u2013306 (2009).","journal-title":"Parkinsonism Relat. Disord."},{"key":"881_CR72","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S1474-4422(20)30394-X","volume":"20","author":"E Jabbari","year":"2021","unstructured":"Jabbari, E. et al. Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study. Lancet Neurol. 20, 107\u2013116 (2021).","journal-title":"Lancet Neurol."},{"key":"881_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2022.105806","volume":"172","author":"G Tsafaras","year":"2022","unstructured":"Tsafaras, G. & Baekelandt, V. The role of LRRK2 in the periphery: link with Parkinson\u2019s disease and inflammatory diseases. Neurobiol. Dis. 172, 105806 (2022).","journal-title":"Neurobiol. Dis."},{"key":"881_CR74","doi-asserted-by":"publisher","first-page":"e51071","DOI":"10.7554\/eLife.51071","volume":"9","author":"CG Weindel","year":"2020","unstructured":"Weindel, C. G. et al. LRRK2 maintains mitochondrial homeostasis and regulates innate immune responses to Mycobacterium tuberculosis. Elife 9, e51071 (2020).","journal-title":"Elife"},{"key":"881_CR75","doi-asserted-by":"publisher","first-page":"e98694","DOI":"10.15252\/embj.201798694","volume":"37","author":"A Hartlova","year":"2018","unstructured":"Hartlova, A. et al. LRRK2 is a negative regulator of Mycobacterium tuberculosis phagosome maturation in macrophages. EMBO J. 37, e98694 (2018).","journal-title":"EMBO J."},{"key":"881_CR76","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1056\/NEJMoa0903753","volume":"361","author":"FR Zhang","year":"2009","unstructured":"Zhang, F. R. et al. Genomewide association study of leprosy. N. Engl. J. Med. 361, 2609\u20132618 (2009).","journal-title":"N. Engl. J. Med."},{"key":"881_CR77","doi-asserted-by":"publisher","first-page":"e1011260","DOI":"10.1371\/journal.ppat.1011260","volume":"19","author":"M Dallmann-Sauer","year":"2023","unstructured":"Dallmann-Sauer, M. et al. Allele-dependent interaction of LRRK2 and NOD2 in leprosy. PLoS Pathog. 19, e1011260 (2023).","journal-title":"PLoS Pathog."},{"key":"881_CR78","doi-asserted-by":"publisher","first-page":"eaai7795","DOI":"10.1126\/scitranslmed.aai7795","volume":"10","author":"KY Hui","year":"2018","unstructured":"Hui, K. Y. et al. Functional variants in the LRRK2 gene confer shared effects on risk for Crohn\u2019s disease and Parkinson\u2019s disease. Sci. Transl. Med. 10, eaai7795 (2018).","journal-title":"Sci. Transl. Med."},{"key":"881_CR79","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1093\/hmg\/ddab138","volume":"30","author":"M Cheung","year":"2021","unstructured":"Cheung, M. et al. Novel LRRK2 mutations and other rare, non-BAP1-related candidate tumor predisposition gene variants in high-risk cancer families with mesothelioma and other tumors. Hum. Mol. Genet. 30, 1750\u20131761 (2021).","journal-title":"Hum. Mol. Genet."},{"key":"881_CR80","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jocn.2017.09.019","volume":"47","author":"Y Kim","year":"2018","unstructured":"Kim, Y. et al. REM sleep behavior disorder portends poor prognosis in Parkinson\u2019s disease: a systematic review. J. Clin. Neurosci. 47, 6\u201313 (2018).","journal-title":"J. Clin. Neurosci."},{"key":"881_CR81","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/978-3-319-49969-7_2","volume":"14","author":"M Kestenbaum","year":"2017","unstructured":"Kestenbaum, M. & Alcalay, R. N. Clinical features of LRRK2 Carriers with Parkinson\u2019s Disease. Adv. Neurobiol. 14, 31\u201348 (2017).","journal-title":"Adv. Neurobiol."},{"key":"881_CR82","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.parkreldis.2020.05.016","volume":"75","author":"A Schrag","year":"2020","unstructured":"Schrag, A. et al. The late stage of Parkinson\u2019s -results of a large multinational study on motor and non-motor complications. Parkinsonism Relat. Disord. 75, 91\u201396 (2020).","journal-title":"Parkinsonism Relat. Disord."},{"key":"881_CR83","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1002\/mds.28274","volume":"35","author":"SY Lim","year":"2020","unstructured":"Lim, S. Y., Lim, K. B., Hor, J. W. & Tan, A. H. Brief clinical rating scales should not be overlooked. Mov. Disord. 35, 1884\u20131885 (2020).","journal-title":"Mov. Disord."},{"key":"881_CR84","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1002\/mds.27974","volume":"35","author":"H Iwaki","year":"2020","unstructured":"Iwaki, H. et al. Penetrance of Parkinson\u2019s Disease in LRRK2 p.G2019S carriers is modified by a polygenic risk score. Mov. Disord. 35, 774\u2013780 (2020).","journal-title":"Mov. Disord."},{"key":"881_CR85","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/ana.26094","volume":"90","author":"D Lai","year":"2021","unstructured":"Lai, D. et al. Genomewide association studies of LRRK2 modifiers of Parkinson\u2019s disease. Ann. Neurol. 90, 76\u201388 (2021).","journal-title":"Ann. Neurol."},{"key":"881_CR86","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1212\/WNL.0000000000000675","volume":"83","author":"F Hentati","year":"2014","unstructured":"Hentati, F. et al. LRRK2 parkinsonism in Tunisia and Norway: a comparative analysis of disease penetrance. Neurology 83, 568\u2013569 (2014).","journal-title":"Neurology"},{"key":"881_CR87","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1002\/mds.28238","volume":"35","author":"T L\u00fcth","year":"2020","unstructured":"L\u00fcth, T. et al. Age at Onset of LRRK2 p.Gly2019Ser is related to environmental and lifestyle factors. Mov. Disord. 35, 1854\u20131858 (2020).","journal-title":"Mov. Disord."},{"key":"881_CR88","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1002\/mds.29563","volume":"38","author":"T Luth","year":"2023","unstructured":"Luth, T. et al. Interaction of mitochondrial polygenic score and lifestyle factors in LRRK2 p.Gly2019Ser Parkinsonism. Mov. Disord. 38, 1837\u20131849 (2023).","journal-title":"Mov. Disord."},{"key":"881_CR89","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.parkreldis.2018.12.014","volume":"62","author":"G Yahalom","year":"2019","unstructured":"Yahalom, G. et al. Carriers of both GBA and LRRK2 mutations, compared to carriers of either, in Parkinson\u2019s disease: risk estimates and genotype-phenotype correlations. Parkinsonism Relat. Disord. 62, 179\u2013184 (2019).","journal-title":"Parkinsonism Relat. Disord."},{"key":"881_CR90","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1002\/mds.28066","volume":"35","author":"N Omer","year":"2020","unstructured":"Omer, N. et al. A possible modifying effect of the G2019S mutation in the LRRK2 Gene on GBA Parkinson\u2019s Disease. Mov. Disord. 35, 1249\u20131253 (2020).","journal-title":"Mov. Disord."},{"key":"881_CR91","doi-asserted-by":"publisher","first-page":"e215845","DOI":"10.1001\/jamanetworkopen.2021.5845","volume":"4","author":"RA Ortega","year":"2021","unstructured":"Ortega, R. A. et al. Association of Dual LRRK2 G2019S and GBA variations With Parkinson Disease Progression. JAMA Netw. Open 4, e215845 (2021).","journal-title":"JAMA Netw. Open"},{"key":"881_CR92","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1002\/mds.29126","volume":"37","author":"AF Schumacher-Schuh","year":"2022","unstructured":"Schumacher-Schuh, A. F. et al. Underrepresented populations in Parkinson\u2019s genetics research: current landscape and future directions. Mov. Disord. 37, 1593\u20131604 (2022).","journal-title":"Mov. Disord."},{"key":"881_CR93","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41531-023-00526-9","volume":"9","author":"LM Lange","year":"2023","unstructured":"Lange, L. M. et al. Elucidating causative gene variants in hereditary Parkinson\u2019s disease in the Global Parkinson\u2019s Genetics Program (GP2). NPJ Parkinsons Dis. 9, 100 (2023).","journal-title":"NPJ Parkinsons Dis."},{"key":"881_CR94","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00439-017-1779-6","volume":"136","author":"PD Stenson","year":"2017","unstructured":"Stenson, P. D. et al. The human gene mutation database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies. Hum. Genet. 136, 665\u2013677 (2017).","journal-title":"Hum. Genet."},{"key":"881_CR95","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/mds.21180","volume":"22","author":"L Ishihara","year":"2007","unstructured":"Ishihara, L. et al. Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson\u2019s disease families. Mov. Disord. 22, 55\u201361 (2007).","journal-title":"Mov. Disord."},{"key":"881_CR96","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/ng.2892","volume":"46","author":"M Kircher","year":"2014","unstructured":"Kircher, M. et al. A general framework for estimating the relative pathogenicity of human genetic variants. Nat. Genet. 46, 310\u2013315 (2014).","journal-title":"Nat. Genet."}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-00881-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-00881-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-00881-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T20:50:54Z","timestamp":1739825454000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-00881-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,17]]},"references-count":96,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["881"],"URL":"https:\/\/doi.org\/10.1038\/s41531-025-00881-9","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,17]]},"assertion":[{"value":"16 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests. C.M. has received honoraria from the Parkinson\u2019s Foundation. C.K. serves as a medical advisor to Centogene and Takeda and previously to Retromer Therapeutics and has received Speakers\u2019 honoraria from Desitin and Bial. K.L. is an Associate Editor at npj Parkinson\u2019s Disease. K.L. was not involved in the journal\u2019s review of, or decisions related to, this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30"}}